Biotech-Turned BNB Treasury Firm Falls 77% After Nasdaq Delisting
Windtree Therapeutics, a biotech company that established a BNB treasury strategy last month, fell 77% on Wednesday after the Nasdaq informed the firm it would be delisted from the stock exchange for failing to meet compliance requirements.The noncompliance concerned Nasdaq Listing Rule 5550(a)(2) that requires a company’s stock to maintain
Read More